A three-pronged analytics strategy

The Medical Informatics World Conference was a great source of knowledge from the field and those who have put analytics at the top of their IT priority list.

“You can build the best recommendation engine in the world and the best possible algorithm but if the company wasn’t ready to execute all that, it would all be for naught,” said Inderpal Bhandari, PhD, senior vice president and chief data officer at Cambia Health Solutions, a large nonprofit which is a conglomerate of 22 companies that reaches 100 million people. 

Thus, strategic alignment between the analytics department and the corporate strategy is critical. From there, a company can develop specific objectives, success metrics and performance metrics. “Then you have the whole organization pushing behind it, and that’s how you do it to scale.”

Bhandari advised the following three approaches to changing corporate culture, which entails “going from a data-as-a-byproduct culture to data-as-an-asset culture”:

  • Top-down sponsorship, or executive support and buy in
  • Bottom-up stewardship, meaning staff from all departments within a company “have to become stewards of the data"
  • Governance to execute strategy

Finding the workforce to carry out analytics remains a challenge, as healthcare organizations often need individuals with mastery in three buckets of knowledge: data science, behavioral science and strategy.

“It’s hard to find talent that spans those three easily,” Bhandari said, adding that some institutions should structure an educational program to encompass all three areas.

Does your organization have an analytics strategy? Please share.

Beth Walsh

Clinical Innovation + Technology editor

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.